Thus, the decreased response to IL-2 in CD25hi cells observed with the rs2104286 risk haplotype in controls, as well as in T cells from subjects with T1D and MS, is not solely a result of reduced surface expression of IL-2RA. This evidence concerns the gene IL2 and myeloid sarcoma.